Related Experiment Video
Updated: Apr 12, 2026
Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
Spinal Myxopapillary Ependymomas Demonstrate a Warburg Phenotype
Stephen C Mack1, Sameer Agnihotri2, Kelsey C Bertrand1
1Developmental & Stem Cell Biology Program, Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada. Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada. Division of Neurosurgery, University of Toronto, Toronto, Ontario, Canada.
Myxopapillary ependymomas exhibit distinct metabolic profiles, suggesting a Warburg phenotype. Key enzymes involved are potential therapeutic targets for this spinal cord tumor.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Cancer Metabolism
Background:
- Myxopapillary ependymoma (MPE) is a spinal cord tumor with a generally good prognosis, but can metastasize and recur.
- Current treatment relies solely on surgical resection.
- Understanding the molecular underpinnings of MPE is crucial for developing new therapies.
Purpose of the Study:
- To investigate the genomic and transcriptional landscape of spinal ependymomas.
- To identify the molecular basis of Myxopapillary ependymoma.
- To discover potential therapeutic targets for MPE.
Main Methods:
- Gene expression and copy number profiling of 35 and 46 spinal ependymomas, respectively.
- Functional assays measuring pyruvate kinase M (PKM), hexokinase (HK) activity, and lactate production.
- Western blot analysis for key metabolic proteins.
Main Results:
- Spinal grade II ependymomas and MPE are molecularly distinct.
- MPE shows increased cellular metabolism with upregulation of HIF1α, HK2, PDK1, and PDHE1A phosphorylation.
- Functional assays confirmed decreased PKM activity, increased HK activity, and elevated lactate production in MPE.
Conclusions:
- MPE may be driven by a Warburg metabolic phenotype.
- Key enzymes (HK2, PKM2, PDK) in this pathway are targetable.
- These enzymes represent promising targets for future MPE clinical trials.
